한미약품
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | KRW 1.2tn | KRW 1.3tn | KRW 1.5tn | KRW 1.5tn | KRW 1.5tn | KRW |
| Operating income | KRW 125.4bn | KRW 158.1bn | KRW 220.7bn | KRW 216.2bn | KRW 257.8bn | KRW |
| Net income | KRW 67.0bn | KRW 82.8bn | KRW 146.2bn | KRW 121.3bn | KRW 169.6bn | KRW |
| Total equity | KRW 802.9bn | KRW 871.9bn | KRW 955.4bn | KRW 1.1tn | KRW 1.2tn | KRW |
| Total liabilities | KRW 1.0tn | KRW 915.4bn | KRW 798.5bn | KRW 780.1bn | KRW 714.7bn | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 125.60 | 104.99 | 83.57 | 71.90 | 57.19 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Show raw values
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | 1,203,185,652,812 | 1,331,546,600,126 | 1,490,887,463,726 | 1,495,501,575,568 | 1,547,531,098,763 | KRW |
| Operating income | 125,415,874,751 | 158,090,311,455 | 220,691,065,020 | 216,186,188,006 | 257,799,090,185 | KRW |
| Net income | 67,025,376,137 | 82,791,735,414 | 146,231,157,748 | 121,315,102,389 | 169,554,330,032 | KRW |
| Total equity | 802,913,730,944 | 871,865,585,833 | 955,442,389,535 | 1,084,893,341,851 | 1,249,756,305,417 | KRW |
| Total liabilities | 1,008,469,278,529 | 915,359,048,755 | 798,457,731,813 | 780,088,902,015 | 714,744,458,123 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준) | 125.60 | 104.99 | 83.57 | 71.90 | 57.19 | % |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 453,000
- 80%
- 420,394.01 ~ 488,888.48
- 90%
- 411,020.23 ~ 505,906.17
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-10-07Filing title as filed투자판단관련주요경영사항 (에페오토인젝터주(에페글레나타이드) 식품의약품안전처 품목허가 승인) original ↗Source: dart_disclosure
- 2026-10-06Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-10-02Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
- 2026-09-29Filing title as filed투자판단관련주요경영사항 original ↗Source: dart_disclosure
- 2026-09-29Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-09-29Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-09-08Filing title as filed기업설명회(IR)개최(안내공시) original ↗Source: dart_disclosure
- 2026-09-08Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-09-08Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-08-28Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-08-26Filing title as filed[기재정정]투자판단관련주요경영사항 (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결) original ↗Source: dart_disclosure
- 2026-08-24Filing title as filed투자판단관련주요경영사항 original ↗Source: dart_disclosure
- 2026-08-21Filing title as filed[기재정정]투자판단관련주요경영사항 original ↗Source: dart_disclosure
- 2026-08-21Filing title as filed[기재정정]투자판단관련주요경영사항 original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-08-12Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-08-11Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-08-11Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-11Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-11Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…